MedTrace Logo

Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma

NCT00353717 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2009-01-13

No results posted yet for this study

Summary

Basal like breast carcinoma is a Her2, estrogen receptor (ER) progesterone receptor (PR) negative breast cancer. It is notable for the high level of epidermal growth factor receptor (EGFR) expression in this tumor subtype .

Thus the investigators wanted to combine the use of anti EGFR therapy in the form of Erbitux (cetuximab) with the widely used weekly taxol chemotherapy for the treatment of these women. This is a small phase I/II study.

Conditions

  • Breast Neoplasms

Interventions

DRUG

cetuximab paclitaxel

weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2

Sponsors & Collaborators

  • Hadassah Medical Organization

    lead OTHER

Principal Investigators

  • Hovav Nechushtan, MD/PHD · Hadassah Ein Kerem Jerusalem

  • Tamar Peretz, MD · Hadassah Ein Kerem

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Completion
2009-09-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00353717 on ClinicalTrials.gov